

**KOPRAN LIMITED**  
**UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 31st DECEMBER, 2013**

Part I Particulars	Quarter ended			Nine Months ended		(₹. in lakhs )
	31/12/2013	30/09/2013	31/12/2012	31/12/2013	31/12/2012	Year ended 31/03/2013
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Net Sales / Income from Operations	7628	7854	5633	21292	16891	24330
Other Operating Income	173	237	142	570	457	692
<b>Total Income from operations</b>	<b>7801</b>	<b>8091</b>	<b>5775</b>	<b>21862</b>	<b>17348</b>	<b>25022</b>
Expenditure						
Changes in Inventories of Finished Goods, Work-in- Progress and stocks- in-trade	204	(371)	(309)	(423)	(708)	(408)
Cost of Materials Consumed	4563	4968	3813	13400	11,255	15,823
Purchase of Stock- in - trade	219	82	-	361	-	-
Employee Benefits Expenses	611	615	536	1750	1,405	2,048
Depreciation	315	308	305	926	903	1,208
Other Expenses	1240	1350	1038	3580	2,989	4,129
<b>Total Expenses</b>	<b>7152</b>	<b>6952</b>	<b>5383</b>	<b>19594</b>	<b>15,844</b>	<b>22,800</b>
<b>Profit (Loss) from operations before other income, Interest and exceptional items</b>	<b>649</b>	<b>1,139</b>	<b>392</b>	<b>2,268</b>	<b>1,504</b>	<b>2,222</b>
Other Income	18	2	68	22	160	205
Foregin Exchange Gain/ (Loss)	1	(263)	50	(158)	(27)	(33)
<b>Profit (Loss) before Interest and exceptional items</b>	<b>668</b>	<b>878</b>	<b>510</b>	<b>2,132</b>	<b>1,637</b>	<b>2,394</b>
Finance Cost	361	375	284	1,043	837	1,188
<b>Profit (Loss) before exceptional items</b>	<b>307</b>	<b>503</b>	<b>226</b>	<b>1,089</b>	<b>800</b>	<b>1,206</b>
Exceptional items	-	-	-	-	-	-
<b>Profit ( Loss ) before tax</b>	<b>307</b>	<b>503</b>	<b>226</b>	<b>1,089</b>	<b>800</b>	<b>1,206</b>
Less :Tax expenses	-	-	-	-	-	-
<b>Net Profit for the period</b>	<b>307</b>	<b>503</b>	<b>226</b>	<b>1,089</b>	<b>800</b>	<b>1,206</b>
Paid up equity share Capital (Face value Rs 10/-)	3,905	3,905	3,905	3,905	3,905	3,905
Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	8,048
<b>Earning Per Share ( EPS ) before and after Exceptional Item</b>						
a) Basic	0.79	1.29	0.58	2.79	2.05	3.09
b) Diluted	0.79	1.29	0.58	2.79	2.05	3.09
<b>Part II</b>						
<b>(A) PARTICULARS OF SHAREHOLDING</b>						
Public shareholding						
Number of shares	23753463	23956538	25809523	23753463	25809523	25510073
Percentage of shareholding	60.83%	61.35%	66.09%	60.83%	66.09%	65.33%
Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered						
Number of shares	3352500	3352500	552500	3352500	552500	1852500
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	21.92%	22.21%	4.17%	21.92%	4.17%	13.68%
Percentage of shares (as a % of the total share capital of the company)	8.59%	8.59%	1.42%	8.59%	1.42%	4.74%
b) Non - encumbered						
Number of shares	11943513	11740438	12687453	11943513	12687453	11686903
Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	78.08%	77.79%	95.83%	78.08%	95.83%	86.32%
Percentage of shares (as a % of the total share capital of the company)	30.58%	30.06%	32.49%	30.58%	32.49%	29.93%
<b>(B) INVESTOR COMPLAINTS</b>	3 Months ended 31/12/2013					
Pending at the beginning of the quarter	-					
Received during the quarter	-					
Disposed off during the quarter	-					
Remaining unresolved at the end of the quarter	-					

Reporting of Segment wise Revenue, Result and Capital Employed						
Particulars	Quarter ended			Nine Months ended		Year ended
	31/12/2013	30/09/2013	31/12/2012	31/12/2013	31/12/2012	31/03/2013
<b>1. Segment Revenue</b>	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(a) Pharmaceutical	8,019	8,207	5,947	22,337	17,905	25,734
(b) Consumer Care Division	67	75	-	185	-	-
<b>Total</b>	<b>8,086</b>	<b>8,282</b>	<b>5,947</b>	<b>22,522</b>	<b>17,905</b>	<b>25,734</b>
Less : Inter-Segment Revenue	-	-	-	-	-	-
Less : Excise Duty	285	191	172	660	557	712
<b>Net Sales/ Income from Operation</b>	<b>7,801</b>	<b>8,091</b>	<b>5,775</b>	<b>21,862</b>	<b>17,348</b>	<b>25,022</b>
<b>2. Segment Results</b>						
(a) Pharmaceutical	742	951	510	2,308	1,637	2,394
(b) Consumer Care Division	(74)	(73)	-	(176)	-	-
<b>Total</b>	<b>668</b>	<b>878</b>	<b>510</b>	<b>2,132</b>	<b>1,637</b>	<b>2,394</b>
Less: Finance Cost	361	375	284	1,043	837	1,188
<b>Total Profit Before Tax</b>	<b>307</b>	<b>503</b>	<b>226</b>	<b>1,089</b>	<b>800</b>	<b>1,206</b>
<b>3. Capital Employed</b>						
(a) Pharmaceutical	21,014	19,827	17,237	21,014	17,237	17,631
(b) Consumer Care Division	258	196	-	258	-	-
(c) Others (Unallocated)	5,425	5,424	5,403	5,425	5,403	5,419
<b>Total</b>	<b>26,697</b>	<b>25,447</b>	<b>22,640</b>	<b>26,697</b>	<b>22,640</b>	<b>23,050</b>

**Notes:-**


(1) The above results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on 13th February, 2014. Limited review has been carried out by statutory auditor of the company.

(2) **Auditors observation:**

a) Investments and Advances made to Subsidiary Company, Kopran Research Laboratories Ltd (KRLL) as at 31-12-2013 amounting to Rs. 5238.42 Lacs, (as at 31-12-2012 Rs 5215.99 Lacs) are in the opinion of the Auditors doubtful of realisation. In the opinion of the Management, no provision is required to be made because the investment in the Subsidiary Company, KRLL, is long term, for strategic reasons.

(3) Figures for the previous accounting period have been regrouped wherever necessary.

**KOPRAN LIMITED**

  
**Surendra Somani**  
 Executive Vice Chairman

Place : Mumbai  
Date : 13-02-2014